Group B was treated with carvedilol (same dosage) and CK at a dosage of 50 mg o.i.d.

Cardiac volumes and ventricular function were assessed by echo at baseline and after 3 and 6 weeks. Quality of life was measured with MLHF questionnaire.

Results: Left ventricular end-diastolic volume (LVEDV) was increased in B group less than in A group after three weeks (p < 0.05) and in B group was under baseline values after six weeks (p < 0.001). Left ventricular ejection fraction (EF) after three and six weeks in B is always greater than A group (p < 0.001).

Dosages of the medications are classified to low, medium and high. Beside the substance-name there is the frequency of usage. The difference to 100% is determined by incomplete answers or by multiple nomination.

Conclusion: Dosages of ACE-inhibitors and diuretics are mostly low to medium, dosage of digitalis is medium most frequently. The dosages of ACE-inhibitors correspond in about 2 to 11% with the recommended (high) doses and are in accordance with those found in international surveys. Given these results we conclude that there is space for improvement of treatment of CHF by Styrian GPs.

Table 3: Digitalis

<table>
<thead>
<tr>
<th></th>
<th>Low</th>
<th>Medium</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digoxin</td>
<td>10%</td>
<td>85%</td>
<td>1%</td>
</tr>
<tr>
<td>Methyldigoxin</td>
<td>10%</td>
<td>85%</td>
<td>1%</td>
</tr>
<tr>
<td>Atenolol</td>
<td>21%</td>
<td>63%</td>
<td>0%</td>
</tr>
<tr>
<td>Digitoxin</td>
<td>15%</td>
<td>38%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Results: Questionnaires were returned by 253 (31%) of the GPs. Dosages of the medications are classified to low, medium and high. Beside the substance-name there is the frequency of usage. The difference to 100% is determined by incomplete answers or by multiple nomination.

Conclusion: Dosages of ACE-inhibitors and diuretics are mostly low to medium, dosage of digitalis is medium most frequently. The dosages of ACE-inhibitors correspond in about 2 to 11% with the recommended (high) doses and are in accordance with those found in international surveys. Given these results we conclude that there is space for improvement of treatment of CHF by Styrian GPs.

P61/10456 Limitation of the excessive extracellular matrix turnover is a major determinant of the beneficial effect of spironolactone on survival in patients with CHF: Insights from the RALES trial

F. Zannad, F. Alla, B. Dousset, B. Pitt. Centre d’Investigation Clinique (CIC), INSERM-CHU Nancy; 1Laboratoire Central de Chimie, CHU Nancy; France; 2University of Michigan, Ann Arbor, United States

Background: In congestive heart failure (CHF), extracellular matrix turnover is a major determinant of cardiac remodeling, diastolic function and pumping capacity. It may be monitored by measuring the serum level of procollagen type III amino-terminal peptide (PIIINP). Animal studies suggested that spironolactone (SPIRO), an aldosterone receptor antagonist may decrease cardiac and vascular fibrosis. Thus, we studied the prognostic significance of PIIINP and its changes during chronic treatment with SPIRO.

Methods: A sample of 261 patients from the RALES trial participated in this substudy (CHF NYHA III and IV, mean age 69, LVEF = 26%, ischemic heart disease = 46%, all were on conventional therapy – 92% on ACE inhibitors). Patients were randomized to placebo or SPIRO 12.5 mg daily. Serum PIIINP was measured at baseline and 6 months after randomization. Mean survival follow up was 24 months. ANOVA and multivariate Cox survival model were used.

Results: Baseline serum PIIINP level was 5.0 μg/l and was similar in the SPIRO and placebo group. At 6 months it decreased in the SPIRO (-17%, p = 0.004), but not in the placebo group. Baseline level > 3.85 μg/l was associated with an increased risk of death only in the placebo group (RR = 2.36 [1.34–4.18], p = 0.003). On the other hand, survival benefit from SPIRO was clustered to patients with above median baseline PIIINP levels (RR = 0.53 [0.35–0.82] vs. 0.90 [0.58–1.40]). These findings were unchanged after adjustment for other prognostic factors.

Conclusion: In patients with CHF, elevated serum PIIINP was significantly associated with excess mortality. SPIRO decreased serum PIIINP and nearly suppressed the excess death risk related to high PIIINP level. It is suggested that limitation of the excessive extracellular matrix turnover is a major determinant of the beneficial effect of SPIRO on survival in patients with CHF.

P62/10460 The acute effect of lisinopril upon left ventricular function in patients with dilated cardiomyopathy

D. Zdrenghea, M. Popescu, D. Timis, D. Pop, A. Papadopoi. Cardiology, Rehabilitation Hospital, Cluj-Napoca, Romania

Angiotensine converting enzyme inhibitors (ACEI) are frequently used in patients (p) with congestive heart failure (CHF), especially dilated cardiomyopathy (DCM). During chronic use ACE improve LV systolic function but the acute effect of ACEI upon LV systolic and especially diastolic function, is less studied, this being the purpose of the present study.

There were studied 23p with DCM, 16 in sinus rhythm and 9 with atrial fibrillation. Any patient wasn’t treated with ACEI the 7 days before the study. An echo Doppler examination was done and LV systolic and diastolic parameters were determined. The examination was repeated 7 hour after administration of a single oral dose of 10 mg lisinopril.

Ejection fraction raised from 37.91 to 45.39% (p < 0.05) and shortening...